Using plant cells as influenza vaccine substrates

References

• WHO. Influenza Vaccines. Wkly Epidem. Rec.75(35), 281–288 (2000).
   Google Scholar
• Options for the use of human H5N1 influenza vaccines and the WHO H5N1 vaccine stockpile. Presented at: WHO Scientific Consultation. Geneva, Switzerland, 1–3 October 2008.
   Google Scholar
• Webby RJ, Perez DR, Coleman JS et al. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet363(9415), 1099–1103 (2004).
   PubMed Web of Science ®Google Scholar
• Schild GC, Oxford JS, de Jong JC, Webster RG. Evidence for host-cell selection of influenza virus antigenic variants. Nature303(5919), 706–709 (1983).
   PubMed Web of Science ®Google Scholar
• Kodihalli S, Justewicz DM, Gubareva LV, Webster RG. Selection of a single amino acid substitution in the hemagglutinin molecule by chicken eggs can render influenza A virus (H3) candidate vaccine ineffective. J. Virol.69(8), 4888–4897 (1995).
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Muller M, Oh HM et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med.358(24), 2573–2584 (2008).
   PubMed Web of Science ®Google Scholar
• Chen MW, Cheng TJ, Huang Y et al. A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc. Natl Acad. Sci. USA105(36), 13538–13543 (2008).
   PubMed Web of Science ®Google Scholar
• Goji NA, Nolan C, Hill H et al. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J. Infect. Dis.198(5), 635–641 (2008).
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Schiff GM, Couch RB et al. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J. Infect. Dis.193(9), 1223–1228 (2006).
   PubMed Web of Science ®Google Scholar
• Huleatt JW, Nakaar V, Desai P et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine26(2), 201–214 (2008).
   PubMed Web of Science ®Google Scholar
• Song L, Nakaar V, Kavita U et al. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS ONE3(5), e2257 (2008).
   PubMed Web of Science ®Google Scholar
• Yusibov V, Mett V, Mett V et al. Peptide-based candidate vaccine against respiratory syncytial virus. Vaccine23(17–18), 2261–2265 (2005).
   PubMed Web of Science ®Google Scholar
• Chichester JA, Musiychuk K, de la Rosa P et al. Immunogenicity of a subunit vaccine against Bacillus anthracis. Vaccine25(16), 3111–3114 (2007).
   PubMed Web of Science ®Google Scholar
• Mett V, Lyons J, Musiychuk K et al. A plant-produced plague vaccine candidate confers protection to monkeys. Vaccine25(16), 3014–3017 (2007).
   PubMed Web of Science ®Google Scholar
• Hull AK, Criscuolo CJ, Mett V et al. Human-derived, plant-produced monoclonal antibody for the treatment of anthrax. Vaccine23(17–18), 2082–2086 (2005).
   PubMed Web of Science ®Google Scholar
• Karasev AV, Foulke S, Wellens C et al. Plant based HIV-1 vaccine candidate: Tat protein produced in spinach. Vaccine23(15), 1875–1880 (2005).
   PubMed Web of Science ®Google Scholar
• Twyman RM, Schillberg S, Fischer R. Transgenic plants in the biopharmaceutical market. Expert Opin Emerg. Drugs10(1), 185–218 (2005).
   PubMedGoogle Scholar
• Kumar S, Daniell H. Engineering the chloroplast genome for hyperexpression of human therapeutic proteins and vaccine antigens. Methods Mol. Biol.267, 365–383 (2004).
   PubMedGoogle Scholar
• Streatfield SJ. Engineered chloroplasts as vaccine factories to combat bioterrorism. Trends Biotechnol.24(8), 339–342 (2006).
   PubMed Web of Science ®Google Scholar
• Yusibov V, Rabindran S, Commandeur U, Twyman RM, Fischer R. The potential of plant virus vectors for vaccine production. Drugs R & D7(4), 203–217 (2006).
   PubMed Web of Science ®Google Scholar
• Fitzmaurice WP, Holzberg S, Lindbo JA et al. Epigenetic modification of plants with systemic RNA viruses. Omics6(2), 137–151 (2002).
   PubMedGoogle Scholar
• Musiychuk K, Stephenson N, Bi H et al. A launch vector for the production of vaccine antigens in plants. Influenza Other Resp. Viruses1, 19–25 (2007).
   PubMed Web of Science ®Google Scholar
• Marillonnet S, Giritch A, Gils M et al.In planta engineering of viral RNA replicons: efficient assembly by recombination of DNA modules delivered by Agrobacterium. Proc. Natl Acad. Sci. USA101(18), 6852–6857 (2004).
   PubMed Web of Science ®Google Scholar
• Chichester JA, Yusibov V. Plants as alternative systems for production of vaccines. Hum. Vaccin.3(4) (2007).
   PubMedGoogle Scholar
• Yusibov V, Rabindran S. Recent progress in the development of plant derived vaccines. Expert Rev. Vaccines7(8), 1173–1183 (2008).
   PubMed Web of Science ®Google Scholar
• Mett V, Farrance CE, Green BJ, Yusibov V. Plants as biofactories. Biologicals36(6), 354–358 (2008).
   PubMed Web of Science ®Google Scholar
• Mett V, Musiychuk K, Bi H et al. A plant-produced influenza subunit vaccine protects ferrets against virus challenge. Influenza Other Resp. Viruses2(1), 33–40 (2008).
   PubMed Web of Science ®Google Scholar
• Shoji Y, Chichester JA, Bi H et al. Plant-expressed HA as a seasonal influenza vaccine candidate. Vaccine26(23), 2930–2934 (2008).
   PubMed Web of Science ®Google Scholar
• Huber VC, McKeon RM, Brackin MN et al. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin. Vaccine Immunol.13(9), 981–990 (2006).
   PubMed Web of Science ®Google Scholar
• Shoji Y, Bi H, Musiychuk K et al. Plant-derived hemagglutinin protects ferrets against challenge infection with the A/Indonesia/05/05 strain of avian influenza. Vaccine (In press) (2009).
   Google Scholar
• Mahmood K, Bright RA, Mytle N et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine26(42), 5393–5399 (2008).
   PubMed Web of Science ®Google Scholar
• Bright RA, Carter DM, Daniluk S et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine25(19), 3871–3878 (2007).
   PubMed Web of Science ®Google Scholar
• D’Aoust ML, PO. Couture, MMJ. et al. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol. J.6, 930–940 (2008).
   PubMed Web of Science ®Google Scholar
• Bright RA, Carter DM, Crevar CJ et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE3(1), e1501 (2008).
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Schiff GM, Hayden FG et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA297(14), 1577–1582 (2007).
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med.354(13), 1343–1351 (2006).
   PubMed Web of Science ®Google Scholar
• Cox MM. Progress on baculovirus-derived influenza vaccines. Curr. Opin Mol. Ther.10(1), 56–61 (2008).
   PubMedGoogle Scholar